Company Analysis

Lineage Cell Therapeutics, Inc. (LCTX)

NYSE: LCTX · Biological Products, (No Diagnostic Substances) · Carlsbad, CA · filing with the SEC since 1996
Grade5.6
◀ Past 6.1● Present 5.5▶ Future 5.3
1 est.

Filings

313 filings since 2017 beside 233 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by May 15, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 43 days after the quarter ended. The proxy statement was last filed Apr 29, 2026.

Filings a yearinsider forms included
6941744835524531
20192020202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 1 time in the last 36 months, the newest Jul 2, 2025.Auditor change (8-K item 4.01): 2 times in the last 36 months, the newest Jun 9, 2025.SEC letters: 2 in the last 36 months, the newest Mar 19, 2026.
Insider forms 233

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 12, 2026 10-Q Quarterly report Sep 30, 2026
Aug 6, 2026 10-Q Quarterly report Jun 30, 2026
Aug 6, 2026 8-K items 2.02, 9.01 Results released · Current report
Jul 29, 2026 SCHEDULE 13G Large holder notice
Jun 12, 2026 8-K items 5.07, 8.01 Shareholder vote; Other event · Current report Jun 9, 2026
May 12, 2026 10-Q Quarterly report Mar 31, 2026
May 12, 2026 8-K items 2.02, 9.01 Results released · Current report
Apr 29, 2026 ARS Annual report to shareholders Dec 31, 2025
Apr 29, 2026 DEFA14A Extra proxy material
Apr 29, 2026 DEF 14A Proxy statement
Mar 23, 2026 EFFECT Registration effective
Mar 19, 2026 CORRESP Reply to the SEC
Mar 16, 2026 UPLOAD SEC comment letter
Mar 11, 2026 S-3 Shelf registration
Mar 11, 2026 8-K items 8.01, 9.01 Other event · Current report
Mar 11, 2026 424B5 Shelf offering
Mar 5, 2026 10-K Annual report Dec 31, 2025
Mar 5, 2026 8-K items 2.02, 9.01 Results released · Current report
Nov 28, 2025 8-K item 8.01 Other event · Current report
Nov 24, 2025 8-K item 8.01 Other event · Current report Nov 20, 2025
Nov 14, 2025 SCHEDULE 13D/A Activist holder update, amended
Nov 12, 2025 8-K item 8.01 Other event · Current report
Nov 12, 2025 424B3 Shelf offering
Nov 6, 2025 10-Q Quarterly report Sep 30, 2025
Nov 6, 2025 8-K items 2.02, 9.01 Results released · Current report
Sep 26, 2025 SCHEDULE 13G Large holder notice
Aug 26, 2025 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report
Aug 15, 2025 S-8 Employee stock plan registration
Aug 12, 2025 10-Q Quarterly report Jun 30, 2025
Aug 12, 2025 8-K items 2.02, 9.01 Results released · Current report
Jul 17, 2025 SCHEDULE 13G/A Large holder update, amended
Jul 2, 2025 8-K items 5.02, 5.07, 9.01 Officer or director change; Shareholder vote · Current report Jun 26, 2025
Jun 23, 2025 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report
Jun 11, 2025 DEFA14A Extra proxy material
Jun 9, 2025 8-K items 4.01, 9.01 Auditor change · Current report Jun 3, 2025
May 13, 2025 10-Q Quarterly report Mar 31, 2025
May 13, 2025 8-K items 2.02, 9.01 Results released · Current report
May 1, 2025 8-K item 8.01 Other event · Current report
Apr 29, 2025 ARS Annual report to shareholders Dec 31, 2024
40 of 313 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton LCTX · research, not advice